Sanofi (FR:SAN) has been in the ranks of Europe’s underperforming pharmaceutical companies for the past few years, as the ...

The sudden departure stands in contrast to other EU pharma leaders who have been given much longer transitions in recent ...

Sanofi abruptly replaced Chief Executive Officer Paul Hudson after a massive research spending boost failed to deliver rapid ...

Sanofi shares fell after the company said Belen Garijo, the chief executive of Germany’s Merck KGaA, would succeed Paul ...

Sanofi’s Board of Directors announced Belén Garijo as the company’s next CEO following the move to not renew the tenure of ...

Sanofi said Belen Garijo, the chief executive of Merck KGaA, would succeed Paul Hudson as CEO after the board of directors decided not to renew Hudson's mandate.

Sanofi is replacing Paul Hudson as CEO, amid questions about which medicines will drive the company's growth in the future.

This board strengthens Serpin Pharma’s ability to advance innovative immune‑modulating therapeutics and expand our ...

Genetically modified immune cells can offer precious additional time to patients with advanced multiple myeloma. However, these therapies lose their impact as the molecules on cancer cells that immune ...

At Davos this year, AI was a key pillar of discussion. Increasingly, people recognize the impact it is already having on innovation and growth. I believe that we will see in the months ahead companies ...

Sanofi’s rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan for the treatment of warm autoimmune hemolytic ...